# Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/phase-i-safety-pharmacokinetics-and-clinical-activity-study-of-lapatinib/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Howard A. Burris,Herbert I. Hurwitz,Elizabeth Claire Dees,Afshin Dowlati,Kimberly Blackwell,Bert H. O’Neil,P. Kelly Marcom,Matthew J. Ellis,Beth Overmoyer,Suzanne F. Jones,Jennifer L. Harris,Deborah A. Smith,Kevin M. Koch,Andrew G. Stead,Steve Mangum,Neil L. Spector |
| Citations | 626 |
| DOI | 10.1200/jco.2005.16.584 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2005.16.584?role=tab |
| OpenAlex ID | https://openalex.org/W2142752401 |
| PMID | 15955900 |
| Type | article |
| Year | 2005 |

## Paper authors

- [Afshin Dowlati](https://scholariq.org/researchers/afshin-dowlati/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Fibroblast Growth Factor Research](https://scholariq.org/topics/fibroblast-growth-factor-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.